Anteris Technologies Global Corp. Files Registration Statement for Proposed US IPO
Anteris Technologies Global Corp. is making moves in the US stock market with a proposed initial public offering (IPO). They’ve filed a Registration Statement with the Securities and Exchange Commission (SEC) for the offering of their common stock. The details like the amount of stock to be offered and the price range are still up in the air, pending market conditions – we’ll have to wait and see for further updates on that front.
Once everything is in place, they plan to list their common stock on the Nasdaq Global Select Market under the symbol “AVR.” And for those Down Under, they intend to list their CHESS Depositary Interests on the Australian Securities Exchange under the same symbol.
Handling the offering are some big names like TD Cowen, Barclays, and Cantor as joint book-running managers, with Lake Street Capital Markets leading the charge.
For those interested in diving deeper, the preliminary prospectus for the offering can be obtained through the respective channels at TD Securities (USA) LLC, Barclays, and Cantor.
Just to make it clear, this announcement is for information purposes only – not an invitation to buy or sell stock just yet. Everything hinges on the registration statement gaining approval from the SEC.
Anteris Technologies Global Corp. is not new to the game. Originally known as Anteris Technologies Ltd, they’re focused on cutting-edge medical devices with their lead product, DurAVR®, a standout in the field of transcatheter heart valves for aortic stenosis. The future looks bright for this company, and we’ll be on the lookout for more updates as they journey into the world of public offerings.
